Work

Prospects of using olokizumab in the treatment of polymyalgia rheumatica: preliminary analysis data

Year: 2025

Type: article

Abstract: BACKGROUND. Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are diseases that develop in people over 50 years of age and often require long—term glucocorticoid (GC) therapy, which is associated with a high risk of side effects. In this regard, it is emergent to search for effective steroid-sparing drugs. Interleukin-6 (IL-6) inhibitors, such as tocilizumab and sarilumab, have already proven efficiency in the treatment of PMR and GCA. However, the availability of these drugs in Russia is limited, what makes the use of a domestic IL-6 inhibitor, olokizumab, promising.

Source: Russian Journal of Geriatric Medicine

DOI: 10.37586/2686-8636-2-2025-265-267

Authors: A. D. Meshkov, A. L. Maslyansky, A. V. Torgashina, I. O. Smitienko, P. I. Novikov, E. P. Ilivanova, A. L. Chudinov, E. G. Zotkin, A. V. Naumov, O. N. Tkacheva

Institutions: Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, St Petersburg University, Association of Rheumatologists of Russia, Sechenov University

Language: English

Topic: Vasculitis and related conditions

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4410168234

FWCI:

Cites:

Cited by:

Related to: 10